Fiche société
Qilu Pharmaceutical Co., Ltd.
Traitements, essais et publications liés.
Traitements17programmes
Essais6liés
Publications46liées
SourceDBlocale
Traitements
17| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Ia:QLS2404 high doseThis study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| Ia:QLS2404 low doseThis study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| Ia:QLS2404 Max doseThis study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| Ia:QLS2404 middle doseThis study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| Ia:QLS2404 very low doseThis study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| Ib:QLS2404 low doseThis study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| liposomal doxorubicinThis phase II trial is studying how well giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide works in treating patients with multiple myeloma that relapsed after autologous stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide may kill more cancer cells. | Cancer, Insuffisance cardiaque, Parkinson | Phase 3 | Thérapie cellulaire | United States | À vérifier |
| paclitaxelThis phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects. | Cancer, Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, … | À vérifier |
| QLS2319Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia | Cancer | Phase 1/2 | À vérifier | China | À vérifier |
| QLS5132The goal of this interventional study is to compare the effectiveness and safety of QLS5132 monotherapy with investigator's choice of chemotherapy in participants with platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. | Cancer | Phase 3 | À vérifier | À vérifier | |
| TopotecanSmall cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, tolerability, and change in disease activity of ABBV-706 compared to standard of care (SOC) treatment (topotecan, lurbinectedin, or amrubicin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are two treatment arms in this study. Participants will either receive ABBV-706 or SOC. Approximately 531 adult participants will be enrolled in the study across 175 sites worldwide. Participants with SCLC will receive intravenous (IV) ABBV-706 or SOC \[topotecan (IV or orally), or lubinectedin (IV), or amrubicin (IV)\]. The estimated duration of the study is approximately 53 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans. | Cancer, Épilepsie | Phase 3 | À vérifier | United States, Austria, Belgium, France, Germany, Greece, Japan, Spain, … | À vérifier |
| liposomal doxorubicinThis phase II trial is studying how well giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide works in treating patients with multiple myeloma that relapsed after autologous stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide may kill more cancer cells. | Cancer | Phase 2 | Thérapie cellulaire | United States | À vérifier |
| Ia:QLS2404 very low doseThis study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. | Lupus | Phase 1 | China | À vérifier | |
| paclitaxelThis phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects. | Parkinson | Phase 1/2 | À vérifier | United States, Brazil, Chile, China, Germany, Italy, Japan, Norway, Singapore, South Korea, Switzerland, Taiwan, Thailand, Turkey (Türkiye) | À vérifier |
| paclitaxelThis phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects. | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| QLS2319Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia | Cancer | Phase 1/2 | À vérifier | China | À vérifier |
| QLS5132The goal of this interventional study is to compare the effectiveness and safety of QLS5132 monotherapy with investigator's choice of chemotherapy in participants with platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. | Cancer | Phase 3 | À vérifier | À vérifier |
Essais cliniques
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| QLS5132 | Cancer | Phase 3 | NCT07926048 | A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NOT_YET_RECRUITING |
| QLS2319 | Cancer | Phase 1/2 | NCT07735104 | The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexia | RECRUITING |
| paclitaxel | Cancer | Phase 2 | NCT06245889 | NeoADAPT — PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC | RECRUITING |
| paclitaxel | Parkinson | Phase 1/2 | NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | RECRUITING |
| Ia:QLS2404 very low dose | Lupus | Phase 1 | NCT07751315 | A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases | NOT_YET_RECRUITING |
| liposomal doxorubicin | Cancer | Phase 2 | NCT01078441 | Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant | TERMINATED |
Publications
46| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Ib:QLS2404 low dose | How to utilise the limited supply of vaccines for Mpox control in Thailand among high-risk GBMSM. | Infectious Disease Modelling | ||
| Ib:QLS2404 low dose | Temperature as a Co-stressor modulating the ecotoxicity of 3,4-dichloroaniline in Daphnia magna. | Aquatic toxicology (Amsterdam, Netherlands) | ||
| Ib:QLS2404 low dose | Design, synthesis, and bioactivity assessment of highly potent isatin-based small-molecules bearing 3-hydrazineyl-6-aryl-1,2,4-triazine moieties as potential c-MET targeting anticancer agents. | Bioorganic chemistry | ||
| Ia:QLS2404 Max dose | An open-label, two-cohort, phase 1a/b study of weekly irinotecan hydrochloride liposome injection combined with vincristine and temozolomide (NALIRI-VT) in patients with advanced Ewing sarcoma. | European journal of cancer (Oxford, England : 1990) | ||
| Ia:QLS2404 Max dose | Pharmacokinetic Drug Interaction Studies of Limnetrelvir with Midazolam and Itraconazole in Healthy Participants. | Clinical drug investigation | ||
| Ia:QLS2404 high dose | Application of 18-glycyrrhetinic acid Fluorescent probes in cell imaging. | Journal of enzyme inhibition and medicinal chemistry | ||
| Ia:QLS2404 middle dose | Transradial versus transfemoral access for diagnostic cerebral angiography: Lesion-specific radiation metrics and outcomes. | Clinical neurology and neurosurgery | ||
| Ia:QLS2404 very low dose | Pain perception and patient tolerance to intra-articular ozone-oxygen injections in the treatment of temporomandibular joint osteoarthritis. | Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery | ||
| Ia:QLS2404 very low dose | Comprehensive evaluation of GdO reinforced polyhydroxybutyrate as a hybrid neutron-gamma shielding material: Spatial dose mapping, photon buildup factors and neutron capture performance under primary and secondary radiation. | Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine | ||
| Topotecan | Poly(glycerol)-modified liposome for co-delivery of pheophorbide a/ topotecan and combination cancer therapy in vivo. | Colloids and surfaces. B, Biointerfaces | ||
| Topotecan | Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis. | Annals of medicine | ||
| Topotecan | Solvent-controlled Rh-catalysed hydrodehalogenation and construction of phenanthridinone skeleton from a common precursor in one-step sequence and the antitumor activity of its derivatives. | Journal of enzyme inhibition and medicinal chemistry | ||
| liposomal doxorubicin | Anti-PEG Single-Chain Variable-Fragment Antibody-Assisted In Vivo Process Decoding of PEGylated Nanomedicines. | ACS nano | ||
| liposomal doxorubicin | Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancer. | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group | ||
| liposomal doxorubicin | Exploiting the dynamics of hyperthermia-enhanced delivery of thermosensitive liposomal doxorubicin to solid tumors. | Drug delivery | ||
| paclitaxel | A phytotherapeutic candidate for neuropathic pain: Helicteres ovata (Lam.) extract shows antinociceptive effects and favorable acute toxicity profile. | Journal of ethnopharmacology | ||
| Ib:QLS2404 low dose | Low-Dose Buprenorphine Initiations During Opioid and Sedative Weaning in Mechanically Ventilated Neurocritical Care Patients: A Retrospective Pilot Cohort Study. | Neurocritical care | ||
| Ib:QLS2404 low dose | Safety and efficacy of recombinant botulinum toxin type A (Eveotox®) in patients with post-stroke upper limb spasticity: Results from a Phase Ib/II clinical trial. | Toxicon : official journal of the International Society on Toxinology | ||
| Ia:QLS2404 Max dose | A randomized controlled phase Ia clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of tofacitinib tartrate cream (HZ-J001) in healthy Chinese subjects. | Frontiers in pharmacology | ||
| Ia:QLS2404 Max dose | Formulation-dependent differences in systemic glutathione availability: Comparative pharmacokinetics of orally dissolving film and tablet formulations in healthy adults. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V | ||
| Ia:QLS2404 high dose | Assessment of Ultraviolet-C Inactivation of and in the Anesthesia Workspace. | Mayo Clinic proceedings. Innovations, quality & outcomes | ||
| Ia:QLS2404 middle dose | Examining the Association Between Internet Addiction and Nonsuicidal Self-Injury Among Chinese Middle School Students: Prospective Cohort Study. | Journal of medical Internet research | ||
| Ia:QLS2404 middle dose | Early use of low dose rituximab in anti acetylcholine receptor generalized myasthenia gravis in South Wales - A retrospective study. | Journal of the neurological sciences | ||
| Ia:QLS2404 very low dose | Soil contamination by metals and radionuclides in missile-affected areas: radiological risk assessment and phytotoxic effects on wheat plants. | Environmental geochemistry and health | ||
| Ia:QLS2404 very low dose | Effects of acute and long-term exercise modalities and doses on brain-derived neurotrophic factor in patients with stroke: a Bayesian network meta-analysis. | Frontiers in systems neuroscience | ||
| liposomal doxorubicin | Radiolabeling of clinically approved nanomedicine carriers: lessons from albumin- and liposome-based systems for biomaterial design and translational imaging. | Nanomedicine (London, England) | ||
| liposomal doxorubicin | Feasibility and Safety of Repeated Intraperitoneal Platinum and Pegylated Liposomal Doxorubicin for First Recurrent Ovarian Cancer: A Preliminary Retrospective Comparative Study. | Cancers | ||
| paclitaxel | DHA Alone, EPA + DHA, EPA + DHA + GLA, and EPA + DHA with or Without Vitamin D During Chemotherapy in Women with Breast Cancer: An Intervention- and Outcome-Stratified Systematic Review. | Nutrients | ||
| paclitaxel | Case Report: Synchronous Esophageal Squamous Cell Carcinoma and Gastric Cardia Adenocarcinoma with Hepatoid Differentiation After Neoadjuvant Chemoimmunotherapy. | Journal of clinical medicine | ||
| paclitaxel | A bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β1 (SHR1701) enhanced preclinical antitumor activity in oral squamous cell carcinoma. | Oral oncology | ||
| paclitaxel | Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial. | Biomolecules & biomedicine | ||
| liposomal doxorubicin | A novel quantification method for unencapsulated doxorubicin in tissues: unlocking PK/PD and TK/TD insights for pegylated liposomal doxorubicin. | Journal of liposome research | ||
| liposomal doxorubicin | Breast cancer risk in female survivors of Hodgkin lymphoma after exposure to non-pegylated liposomal doxorubicin at young adult and adult age: the first real-life series from Southern Italy cancer centers. | Annals of hematology | ||
| paclitaxel | Photothermal and photo-oxidation mediated release of lipophilic paclitaxel from liposomes: from formulation to in vitro efficacy and molecular dynamics simulations? | International journal of pharmaceutics | ||
| paclitaxel | Paclitaxel's Broken Promise for Dialysis Access: The ABISS Trial. | European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery | ||
| liposomal doxorubicin | Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | ||
| paclitaxel | Capmatinib and paclitaxel combination: a novel strategy for overcoming challenges in triple-negative breast cancer treatment. | BMC cancer | ||
| paclitaxel | Repurposed anticancer drugs disrupt cancer-like traits of Theileria annulata and suppress Leishmania donovani. | Cell communication and signaling : CCS | ||
| liposomal doxorubicin | A Novel Capillary Electrophoresis Capacitively Coupled Contactless Conductivity Detection (CE‑CD) Method for Quantification of Ionic Excipients in Doxorubicin HCl Liposome Injection. | ACS omega | ||
| liposomal doxorubicin | Dexamethasone for PEGylated liposomal doxorubicin cutaneous toxicity: Denominators, regimen identity, and implementation. | Journal of controlled release : official journal of the Controlled Release Society | ||
| paclitaxel | Therapeutic Effect of Parthenolide on Paclitaxel-Induced Cardiotoxicity in Rats. | Journal of cellular biochemistry | ||
| paclitaxel | ROS-Activatable "off-on" Fluorescent Prodrug Loaded Micelles for Targeted Therapy and in Situ Imaging of Breast Cancer Cells. | International journal of pharmaceutics: X | ||
| paclitaxel | Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study. | BMJ oncology | ||
| paclitaxel | Paclitaxel in oncology: balancing anticancer efficacy with potential carcinogenic risks and resistance mechanisms. | Naunyn-Schmiedeberg's archives of pharmacology | ||
| paclitaxel | Incidence and clinical characteristics of taxane-induced peripheral neuropathy requiring treatment in patients with breast cancer. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | ||
| paclitaxel | Paclitaxel and B7-H6 knockdown inhibit HepG2 hepatocellular carcinoma cell viability and migration, while enhancing apoptosis and cell cycle arrest. | Molecular biology reports |